Skip to main
MRK

Merck (MRK) Stock Forecast & Price Target

Merck (MRK) Analyst Ratings

Based on 18 analyst ratings
Buy
Strong Buy 22%
Buy 39%
Hold 39%
Sell 0%
Strong Sell 0%

Bulls say

Merck & Co is a leading global biopharmaceutical company, with a positive outlook due to its diverse portfolio of drugs and vaccines, including its successful immuno-oncology platform led by Keytruda. The recent data from the CADENCE study for Winrevair in Group 2 PH showed exceptional results, and the company's pipeline has a strong catalyst calendar with promising drugs in various stages of development. Additionally, Merck's comprehensive diversity programs and focus on attracting diverse talent should further drive business success. However, there are potential risks to consider, such as unsuccessful commercialization of new growth drivers and generic/biosimilar competition.

Bears say

Merck & Co is expected to experience modest revenue growth in 2026, but this may be surpassed due to management's track record and low expectations. The acquisition of Cidara Therapeutics adds potential peak sales of over $5 billion to MRK's pipeline, and the company's optimization initiative could result in annual savings of $3 billion by the end of 2027, which will be reinvested in strategic growth areas. With a clear win from its CADENCE program and additional growth drivers in the pharmaceutical and vaccine markets, MRK is well-positioned to navigate through LOE in late-2028 and reignite growth in the early-2030s. We anticipate multiple expansion as MRK deploys cash flow into R&D and potential M&A, driving enthusiasm and consensus upgrades over the next 12-18 months.

Merck (MRK) has been analyzed by 18 analysts, with a consensus rating of Buy. 22% of analysts recommend a Strong Buy, 39% recommend Buy, 39% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Merck and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Merck (MRK) Forecast

Analysts have given Merck (MRK) a Buy based on their latest research and market trends.

According to 18 analysts, Merck (MRK) has a Buy consensus rating as of May 15, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $125, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $125, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Merck (MRK)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.